On April 6, 2026, Neurocrine Biosciences and Soleno Therapeutics announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.
The acquisition of Soleno and the addition of VYKAT™ XR (diazoxide choline), a first-in-class therapy to treat hyperphagia, the defining feature of Prader-Willi syndrome, will expand Neurocrine's portfolio of innovative medicines and strengthen its leadership position in endocrinology and rare disease.
The boards of directors of both companies have approved the transaction, which is expected to close within 90 days, subject to satisfaction of customary closing conditions.
Wilson Sonsini’s relationship with Soleno extends back to the company’s formation in 1998. Since then, we have supported Soleno as its external general counsel and strategic advisor, representing the company in all of its transactions, including venture financings, numerous acquisitions, initial public offering, and numerous equity and debt offerings. We are proud to have partnered with Soleno throughout its life cycle.
The Wilson Sonsini team that is advising Soleno is led by Elton Satusky, Rob Ishii, Catherine Riley Tzipori, and Doug Schnell. The team also includes:
Corporate/M&A
Ryan Cooper
Rayna Guo
Kevin Roesser
Jessica Li
Yifeng Li
Technology Transactions
Seth Flaum
Aleksandar Vitomirov
Kimberly Parry
Katie Gu
Jacqueline Ito
Natalie Juo
Vincent Bai
FDA Regulatory
Eva Yin
Tax
Myra Sutanto Shen
Anjali Krishnan
Employee Benefits and Compensation
Brandon Gantus
Michael Klippert
Jason Chan
Emma Wilcox
Laura Yun
Sophia Friedfertig
Employment Law
Matt Gorman
Quinn Christie
Data, Privacy, and Cybersecurity
Matt Staples
Michael O’Brien
Dan Shin
National Security
Anne Seymour
Seth Cowell
Nimit Dhir
Antitrust and Competition
Jamillia Ferris
Michelle Yost Hale
Kimberley Biagioli
Miata Eggerly
Real Estate
James McCann
Alex Corluyan
Martin Sul
Corporate Finance
Kathleen Rothman
Jill Fulwiler
Ryan Isola
For more information, please see Neurocrine's news release. Additional coverage can be found on Bloomberg, Fierce Pharma, and STAT.
